No Increase In Diabetes Found With Ezetimibe In IMPROVE-IT
A new analysis of the IMPROVE-IT trial found no significant increase in the rate of new onset diabetes in patients taking ezetimibe. Michael Blazing of Duke University presented the results of the IMPROVE-IT substudy on Tuesday afternoon at the European Society of Cardiology meeting in London. The analysis was prompted by previous findings from very...Click here to continue reading...
Source: CardioBrief - Category: Cardiology Authors: Larry Husten Tags: Policy & Ethics Prevention, Epidemiology & Outcomes cholesterol diabetes ezetimibe IMPROVE-IT Simvastatin Source Type: blogs
More News: Cardiology | Cholesterol | Diabetes | Endocrinology | Epidemiology | Heart | Medical Ethics | Simvastatin | Statin Therapy | Vytorin | Zetia | Zocor